"Investigators from 12 countries presented consistent results with diagnostic yields of nearly 70 percent, demonstrating that video capsule endoscopy
represents a revolutionary, rather than evolutionary, step forward in patient management", said David Cave, M.D., a gastroenterologist at St. Elizabeth's
Medical Center, Boston, Mass. "As a result of the data presented at the Rome conference, it is now clear that the M2A capsule will be the test of choice after
upper and lower endoscopy, he added. Ahead of the termination of the lockup for Given Imaging insider shareholders, the company's shares temporarily
slumped to $9, and had rebounded to above $13 by the end of the third week of April.
Given Imaging recently announced that sales of its Given Diagnostic System and M2AŽ capsule endoscope exceeded $5.0 million in the first quarter of 2002.
The company was host to more than 90 physicians from 12 countries gathered in Rome recently.
They attended the first Given Imaging (NASDAQ: GIVN) Conference on Capsule Endoscopy. The meeting of internal investigators offered a forum for the
exchange of scientific and clinical experience for physicians using the M2A Capsule Endoscope, an ingestible color video mini camera that visualizes the small
intestine in a revolutionary development.
Leading gastroenterologists from the United States, Europe and Israel drew on experiences from more than 850 capsule endoscopy procedures. They
delivered nearly 60 presentations during the three-day conference. Presentations demonstrated usage of the capsule to diagnose a wide variety of
conditions in the small bowel including Crohn's disease, celiac/sprue, unexplained abdominal pain, nonsteroidal anti-inflammatory drug (NSAID) injury,
polyposis, intestinal tumors, iron deficiency anemia and obscure bleeding.